Abbott has secured FDA clearance for its highly sensitive troponin blood test, which aims to identify heart attacks hours earlier than previous methods. Its Architect Stat test searches for small ...
The US Food and Drug Administration (FDA) has approved the Architect Stat (Abbott Laboratories) high-sensitivity troponin-I assay, which can detect myocardial infarction (MI) faster and more ...
Abbott Laboratories (NYSE:ABT) recently attained the FDA approval for its ARCHITECT STAT High Sensitivity Troponin-I blood test. This is one of the most meticulously-researched troponin diagnostic ...
ABBOTT PARK, Ill., Sept. 25, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug ...
Abbott Park, IL - Abbott Laboratories announced FDA approval for a troponin-I (TnI) test for use on Abbott's ARCHITECT ® i2000SR ® Immunoassay System and ARCHITECT ci8200 TM Immunochemistry System.
Abbott ABT announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and ...
FierceBiotech: Abbott's highly sensitive troponin blood test for heart attacks cleared by FDA
Abbott's highly sensitive troponin blood test for heart attacks cleared by FDA
FiercePharma: Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay
Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay
FiercePharma: New Data for Abbott's Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
HOUSTON, /PRNewswire/ -- Abbott (NYSE: ABT) announced today promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay presented at this year's American ...